Towards  ||| S:0 E:8 ||| IN
targeted  ||| S:8 E:17 ||| JJ
epigenetic  ||| S:17 E:28 ||| JJ
therapy  ||| S:28 E:36 ||| NN
of  ||| S:36 E:39 ||| IN
cancer  ||| S:39 E:46 ||| NN
Increasing  ||| S:46 E:57 ||| VBG
number  ||| S:57 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
publications  ||| S:67 E:80 ||| NNS
in  ||| S:80 E:83 ||| IN
the  ||| S:83 E:87 ||| DT
last  ||| S:87 E:92 ||| JJ
10  ||| S:92 E:95 ||| CD
years  ||| S:95 E:101 ||| NNS
implicated  ||| S:101 E:112 ||| VBN
that  ||| S:112 E:117 ||| IN
cancer  ||| S:117 E:124 ||| NN
development  ||| S:124 E:136 ||| NN
depends ||| S:136 E:143 ||| VBZ
,  ||| S:143 E:145 ||| ,
except  ||| S:145 E:152 ||| IN
genetic  ||| S:152 E:160 ||| JJ
alterations ||| S:160 E:171 ||| NN
,  ||| S:171 E:173 ||| ,
also  ||| S:173 E:178 ||| RB
on  ||| S:178 E:181 ||| IN
inheritable  ||| S:181 E:193 ||| JJ
gene  ||| S:193 E:198 ||| NN
expression  ||| S:198 E:209 ||| NN
patterns  ||| S:209 E:218 ||| NNS
that  ||| S:218 E:223 ||| WDT
are  ||| S:223 E:227 ||| VBP
not  ||| S:227 E:231 ||| RB
bound  ||| S:231 E:237 ||| VBN
to  ||| S:237 E:240 ||| TO
DNA  ||| S:240 E:244 ||| NNP
sequence  ||| S:244 E:253 ||| NN
alterations ||| S:253 E:264 ||| NN
.  ||| S:264 E:266 ||| .
These  ||| S:266 E:272 ||| DT
epigenetic  ||| S:272 E:283 ||| JJ
mechanisms  ||| S:283 E:294 ||| NNS
manifest  ||| S:294 E:303 ||| VBP
mostly  ||| S:303 E:310 ||| RB
through  ||| S:310 E:318 ||| IN
changes  ||| S:318 E:326 ||| NNS
in  ||| S:326 E:329 ||| IN
chromatin  ||| S:329 E:339 ||| JJ
packing  ||| S:339 E:347 ||| NN
and  ||| S:347 E:351 ||| CC
in  ||| S:351 E:354 ||| IN
localized  ||| S:354 E:364 ||| JJ
gene  ||| S:364 E:369 ||| NN
promoter  ||| S:369 E:378 ||| NN
changes  ||| S:378 E:386 ||| NNS
that  ||| S:386 E:391 ||| WDT
influence  ||| S:391 E:401 ||| VBP
the  ||| S:401 E:405 ||| DT
transcription  ||| S:405 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
the  ||| S:422 E:426 ||| DT
genes  ||| S:426 E:432 ||| NNS
involved  ||| S:432 E:441 ||| VBN
in  ||| S:441 E:444 ||| IN
carcinogenesis ||| S:444 E:458 ||| NN
.  ||| S:458 E:460 ||| .
These  ||| S:460 E:466 ||| DT
changes  ||| S:466 E:474 ||| NNS
are  ||| S:474 E:478 ||| VBP
mitoticaly  ||| S:478 E:489 ||| JJ
inheritable  ||| S:489 E:501 ||| NN
and  ||| S:501 E:505 ||| CC
potentially  ||| S:505 E:517 ||| RB
reversible ||| S:517 E:527 ||| JJ
,  ||| S:527 E:529 ||| ,
providing  ||| S:529 E:539 ||| VBG
large  ||| S:539 E:545 ||| JJ
possibilities  ||| S:545 E:559 ||| NNS
of  ||| S:559 E:562 ||| IN
epigenetic  ||| S:562 E:573 ||| JJ
therapy  ||| S:573 E:581 ||| NN
of  ||| S:581 E:584 ||| IN
cancer ||| S:584 E:590 ||| NN
.  ||| S:590 E:592 ||| .
So  ||| S:592 E:595 ||| RB
far  ||| S:595 E:599 ||| RB
this  ||| S:599 E:604 ||| DT
therapy  ||| S:604 E:612 ||| NN
lacks  ||| S:612 E:618 ||| VBZ
specificity  ||| S:618 E:630 ||| VBN
of  ||| S:630 E:633 ||| IN
targeting  ||| S:633 E:643 ||| VBG
certain  ||| S:643 E:651 ||| JJ
genes ||| S:651 E:656 ||| NNS
.  ||| S:656 E:658 ||| .
Instead ||| S:658 E:665 ||| RB
,  ||| S:665 E:667 ||| ,
epigenetic  ||| S:667 E:678 ||| JJ
therapy  ||| S:678 E:686 ||| NN
attempts  ||| S:686 E:695 ||| VBZ
either  ||| S:695 E:702 ||| RB
to  ||| S:702 E:705 ||| TO
reactivate  ||| S:705 E:716 ||| VB
or  ||| S:716 E:719 ||| CC
to  ||| S:719 E:722 ||| TO
silence  ||| S:722 E:730 ||| VB
genes  ||| S:730 E:736 ||| NNS
that  ||| S:736 E:741 ||| WDT
are  ||| S:741 E:745 ||| VBP
important  ||| S:745 E:755 ||| JJ
for  ||| S:755 E:759 ||| IN
the  ||| S:759 E:763 ||| DT
cancer  ||| S:763 E:770 ||| NN
progress ||| S:770 E:778 ||| NN
.  ||| S:778 E:780 ||| .
Epigenetic  ||| S:780 E:791 ||| JJ
therapy  ||| S:791 E:799 ||| NN
of  ||| S:799 E:802 ||| IN
cancer  ||| S:802 E:809 ||| NN
is  ||| S:809 E:812 ||| VBZ
based  ||| S:812 E:818 ||| VBN
mostly  ||| S:818 E:825 ||| RB
on  ||| S:825 E:828 ||| IN
the  ||| S:828 E:832 ||| DT
usage  ||| S:832 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
inhibitors  ||| S:841 E:852 ||| NN
of  ||| S:852 E:855 ||| IN
DNA  ||| S:855 E:859 ||| NNP
methyltransferases  ||| S:859 E:878 ||| NNS
( ||| S:878 E:879 ||| -LRB-
DNMTs ||| S:879 E:884 ||| NNP
) ||| S:884 E:885 ||| -RRB-
,  ||| S:885 E:887 ||| ,
histone  ||| S:887 E:895 ||| FW
deacetylase  ||| S:895 E:907 ||| FW
( ||| S:907 E:908 ||| -LRB-
HDAC ||| S:908 E:912 ||| NNP
)  ||| S:912 E:914 ||| -RRB-
inhibitors  ||| S:914 E:925 ||| NN
and  ||| S:925 E:929 ||| CC
anti-micro-RNA  ||| S:929 E:944 ||| JJ
therapy ||| S:944 E:951 ||| NN
.  ||| S:951 E:953 ||| .
Developments  ||| S:953 E:966 ||| NNS
that  ||| S:966 E:971 ||| WDT
involve  ||| S:971 E:979 ||| VBP
integration  ||| S:979 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
the  ||| S:994 E:998 ||| DT
latest  ||| S:998 E:1005 ||| JJS
technological  ||| S:1005 E:1019 ||| JJ
advances ||| S:1019 E:1027 ||| NNS
,  ||| S:1027 E:1029 ||| ,
such  ||| S:1029 E:1034 ||| JJ
as  ||| S:1034 E:1037 ||| IN
whole  ||| S:1037 E:1043 ||| JJ
genome  ||| S:1043 E:1050 ||| JJ
microarray  ||| S:1050 E:1061 ||| JJ
expression  ||| S:1061 E:1072 ||| NN
profiling ||| S:1072 E:1081 ||| NN
,  ||| S:1081 E:1083 ||| ,
help  ||| S:1083 E:1088 ||| VB
identify  ||| S:1088 E:1097 ||| VB
mechanisms  ||| S:1097 E:1108 ||| NNS
of  ||| S:1108 E:1111 ||| IN
action  ||| S:1111 E:1118 ||| NN
of  ||| S:1118 E:1121 ||| IN
epigenetic  ||| S:1121 E:1132 ||| JJ
drugs ||| S:1132 E:1137 ||| NNS
,  ||| S:1137 E:1139 ||| ,
leading  ||| S:1139 E:1147 ||| VBG
to  ||| S:1147 E:1150 ||| TO
development  ||| S:1150 E:1162 ||| NN
of  ||| S:1162 E:1165 ||| IN
second  ||| S:1165 E:1172 ||| JJ
generation  ||| S:1172 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
epi-drugs  ||| S:1186 E:1196 ||| NN
which  ||| S:1196 E:1202 ||| WDT
would  ||| S:1202 E:1208 ||| MD
have  ||| S:1208 E:1213 ||| VB
greater  ||| S:1213 E:1221 ||| JJR
specificity  ||| S:1221 E:1233 ||| NN
and  ||| S:1233 E:1237 ||| CC
efficacy ||| S:1237 E:1245 ||| NN
.  ||| S:1245 E:1247 ||| .
The  ||| S:1247 E:1251 ||| DT
obtained  ||| S:1251 E:1260 ||| JJ
results  ||| S:1260 E:1268 ||| NNS
are  ||| S:1268 E:1272 ||| VBP
promising ||| S:1272 E:1281 ||| VBG
,  ||| S:1281 E:1283 ||| ,
leaving  ||| S:1283 E:1291 ||| VBG
great  ||| S:1291 E:1297 ||| JJ
possibilities  ||| S:1297 E:1311 ||| NNS
for  ||| S:1311 E:1315 ||| IN
improvement  ||| S:1315 E:1327 ||| NN
of  ||| S:1327 E:1330 ||| IN
cancer  ||| S:1330 E:1337 ||| NN
therapy ||| S:1337 E:1344 ||| NN
.  ||| S:1344 E:1346 ||| .
